MA-ULTIVUE/INDIVUMED
18.11.2020 15:19:08 CET | Business Wire | Press release
Ultivue and Indivumed today announced that the two companies have entered into a collaborative partnership to further accelerate research and drug development in the area of personalized oncology.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005281/en/
The deal links Indivumed’s vast array of standardized and fully comparable tissue biospecimens and analytical experience in IHC technology with Ultivue’s InSituPlex platform for high-throughput multiplex immunofluorescence. Ultivue’s standardized assay development for whole tissue phenotyping, when combined with Indivumed’s multi-omics oncology tissue biobank and capabilities to perform IHC multiplex assays, will enable deeper insights into tumor biology, unveiling complex mechanisms of cancer.
“By bringing Ultivue’s technology and expertise into our workflow, we’re giving our customers access to the contextual profiling of key cellular phenotypes,” says Prof. Dr. Hartmut Juhl, founder and CEO of Indivumed. “The data that can now be extracted from these valuable assets in our repository can support the full characterization of samples for biomarker and target discovery, drug development, clinical trials, and individualized therapy research. It will complete our offer in combination with the existing broad menu of IHC assays and end-to-end service”
Cambridge-based UItivue’s InSituPlex multiplexing technology is designed for fast and comprehensive exploration of biologically-relevant markers in tissue samples.
“InSituPlex is built to derive more biologically-relevant data from patient tissue samples at scale,” notes Jacques Corriveau, President and CEO of Ultivue. “By providing Indivumed with this capability and complementing its extensive biospecimen resources, we can enable researchers to rapidly assess the clinical utility of tissue biomarkers to increase the success of clinical trials in the I/O space.”
About Indivumed:
Indivumed is a physician-led, integrated global oncology company committed to unveiling complex mechanisms of cancer, in order to support precision oncology. Only a multi-omics approach can achieve this goal – and reliable multi-omics require especially high-quality biospecimens and data. Through its three divisions, IndivuServ, IndivuType, and IndivuTest, Indivumed offers specialized products and services that support customers in biomarker and target discovery, drug development, clinical trials, individualized therapy and more.
Indivumed is headquartered in Hamburg, Germany, with a US-based subsidiary and a global clinical network.
About Ultivue:
Ultivue provides researchers and scientists with multiplex biomarker assays for tissue phenotyping and digital pathology. Its proprietary InSituPlex technology enables advanced exploration and interrogation of tissue samples for precision medicine research. These highly customizable solutions and Ultivue’s scientific consultative approach strengthen and accelerate biomarker discovery and drug development programs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005281/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Capcom’s Official Street Fighter 6 World Championship Tournaments Attract Record-high 20,000 Attendees16.3.2026 14:00:00 CET | Press release
– Capcom aims to accelerate growth of the global competitive scene with a larger total prize pool of over $2.1 million in the upcoming 2026 season – Capcom Co., Ltd. (TOKYO:9697) today announced that Capcom Cup 12 and Street Fighter League: World Championship 2025, its official world championship tournaments to determine the top Street Fighter 6 competitors, which were held at Ryogoku Kokugikan Arena from March 11-15, achieved a record-high of 20,000 attendees, concluding with great success. At Capcom Cup 12, which features matches against individual players, SAHARA (21 years old), who is a first‑year professional player, claimed the championship title in his debut appearance, while in the team-based competition Street Fighter League: World Championship 2025, Japanese representatives REJECT were the winning team. Capcom additionally announced that it will hold next season’s Capcom Cup 13 and Street Fighter League: World Championship 2026 at Ryogoku Kokugikan Arena. Furthermore, the com
Capcom’s Resident Evil Requiem Sales Exceed 6 Million Units!16.3.2026 14:00:00 CET | Press release
– Capcom also plans to release additional game content – Capcom Co., Ltd. (TOKYO:9697) today announced that worldwide sales of Resident Evil Requiem, released on February 27, 2026, now exceed 6 million units, which is the fastest that a title in the series has reached this milestone. Resident Evil Requiem is the latest installment in the Resident Evil series, which offers photorealistic visuals and a deep sense of immersion. Players can enjoy the elevated essence of the survival horror experience by the interplay between intense fear and exhilarating action, made possible by two protagonists. Going forward, Capcom plans to implement several measures, such as ongoing support and additional game content, so players can continue to enjoy the title longer. In addition, the Resident Evil series will celebrate its 30th anniversary on March 22,2026. Capcom is readying various plans for this anniversary to delight series fans, such as a collaboration between Universal Studios Japan and Residen
Helical Fusion Announces Construction Site for Phase 1 of “Helix HARUKA,” Marking Transition to Manufacturing and Assembly of Fusion Hardware16.3.2026 14:00:00 CET | Press release
Advances one of Japan’s leading public-private partnership initiatives for fusion commercialization with NIFS and industrial partners Helical Fusion Co., Ltd. (Head Office: Chuo-ku, Tokyo; CEO: Takaya Taguchi; “Helical Fusion”), a Japanese fusion energy company advancing the Helix Program and developing the Helical Stellarator for commercial fusion power plants, announced the construction site for Phase 1 of Helix HARUKA, its Integrated Demonstration Device. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316066384/en/ Concept image of Helix HARUKA, Helical Fusion’s integrated demonstration device Phase 1—the magnet demonstration phase—will be built in a dedicated workspace for the joint research group formed by Helical Fusion and the National Institute for Fusion Science (NIFS), located on the NIFS campus. Helical Fusion has already begun manufacturing phase and site build-out, with the aim of conducting coil current (ene
HyperLight Demonstrates Low-Power 1.6T-DR8 TFLN-based Reference Transceiver Assembled by TFC16.3.2026 13:03:00 CET | Press release
HyperLight Corporation (“HyperLight”) today announced a major milestone in low-power optical networking with the demonstration of a 1.6T-DR8 optical transceiver leveraging HyperLight’s TFLN Chiplet™ Platform. The reference module was demonstrated with engineering and manufacturing support from Suzhou TFC Optical Communication Co., Ltd. (SZSE: 300394, or "TFC"). The reference design achieves 20W power consumption in a fully retimed 1.6T-DR8 module, representing approximately 20% lower module-level power compared to alternative technologies. The reduction is achieved through a simple drop-in transmitter implementation based on a single thin-film lithium niobate photonic integrated circuit (TFLN PIC). The TFLN transmitter enables the module to operate using a single continuous-wave (CW) laser, compared to the two to four lasers typically required in conventional implementations. Additional energy savings are achieved through the ability to operate directly from the native low-swing electr
GCE® Launches Gascontrol.com Website Showcasing Its Complete Gas Control Portfolio for Speciality, Medical, and Industrial Applications16.3.2026 13:00:00 CET | Press release
GCE®, a global market leader for gas control equipment, has launched gascontrol.com, a new website designed to better serve customers across its GCE Specialty, GCE Medical, and GCE Industrial product portfolios. The new site provides a streamlined, market-focused experience that makes it easier for users to explore GCE’s gas control solutions and identify the right products. A new Documentation Search Tool assists customers in easily finding documents such as instructions for use (IFUs), appendices, and certifications through an intuitive search interface. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260316410525/en/ GCE’s new website, gascontrol.com, provides a streamlined, market-focused experience across the GCE Specialty, GCE Medical, and GCE Industrial product portfolios. “The redesigned website reflects GCE’s role as a comprehensive, trusted supplier of gas control technologies that elevate industries and improve liv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom